Contract Manufacturing DNA Drugs Protein 
Roots Analysis
FEBRUARY 27, 2024
On November 1, 2019, Avacta Group and ADC Therapeutics have announced a collaboration agreement for the development of novel drug candidates. The firm also has the right to obtain exclusive licenses to the Affimer proteins for clinical development and commercialization.
Roots Analysis
JANUARY 14, 2024
With the increased interest and gradual shift of investment from small molecule drugs to biologics and the establishment of several biologics manufacturing companies / biologics CMOs, more than 250 biologic therapies and vaccines have been developed, globally. Like all drugs, biologics are regulated by the FDA.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Roots Analysis
FEBRUARY 18, 2022
In the 20 th century, major research went into discovery of a therapeutic class with the primary purpose of interfering with the RNA expression linked to disease causing proteins, nowadays classified as oligonucleotides. These contract service providers are actively entering into strategic collaborations to augment their existing portfolios.
The Pharma Data
MARCH 22, 2022
Pfizer continues to invest to support the manufacturing and distribution of PAXLOVID, including exploring potential contract manufacturing options. In preclinical studies, nirmatrelvir did not demonstrate evidence of mutagenic DNA interactions.
Drug Discovery World
SEPTEMBER 6, 2022
There’s no doubt that cell and gene therapies present some of the most exciting opportunities for emerging drugs. Among these include Zolgensma, Novartis’ gene therapy drug for spinal muscular atrophy (SMA), which made headlines in the UK for its £1.79 million price point per dose.
Roots Analysis
FEBRUARY 13, 2023
Messenger ribonucleic acid (mRNA) is a single-stranded molecule, which carries coding sequence and plays a prominent role in protein synthesis. It transfers genetic information form to DNA to ribosomes, a specialized structure, or organelle, which decodes genetic information into a protein.
XTalks
FEBRUARY 11, 2021
The increased production aims will be achieved through both improved manufacturing efficiency and increasing build capacity. The drugmaker is targeting various steps in the manufacturing process, beginning right at the DNA stage, which is required as the template from which the mRNA for the SARS-CoV-2 spike protein in the vaccine is made.
Expert insights. Personalized for you.
52 
Let's personalize your content